Akero Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Akero Therapeutics CEO'su Andrew Cheng, Sep2018 tarihinde atandı, in görev süresi 6.17 yıldır. in toplam yıllık tazminatı $ 8.83M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.5% maaş ve 92.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.72% ine doğrudan sahiptir ve bu hisseler $ 17.53M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.8 yıl ve 5.6 yıldır.

Anahtar bilgiler

Andrew Cheng

İcra Kurulu Başkanı

US$8.8m

Toplam tazminat

CEO maaş yüzdesi	7.5%
CEO görev süresi	6.2yrs
CEO sahipliği	0.7%
Yönetim ortalama görev süresi	5.8yrs
Yönetim Kurulu ortalama görev süresi	5.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Andrew Cheng'un ücretlendirmesi Akero Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$204m
Mar 31 2024	n/a	n/a	-US$179m
Dec 31 2023	US$9m	US$660k	-US$152m
Sep 30 2023	n/a	n/a	-US$120m
Jun 30 2023	n/a	n/a	-US$116m
Mar 31 2023	n/a	n/a	-US$112m
Dec 31 2022	US$10m	US$624k	-US$112m
Sep 30 2022	n/a	n/a	-US$121m
Jun 30 2022	n/a	n/a	-US$110m
Mar 31 2022	n/a	n/a	-US$112m
Dec 31 2021	US$4m	US$570k	-US$101m
Sep 30 2021	n/a	n/a	-US$98m
Jun 30 2021	n/a	n/a	-US$95m
Mar 31 2021	n/a	n/a	-US$82m
Dec 31 2020	US$5m	US$523k	-US$79m
Sep 30 2020	n/a	n/a	-US$65m
Jun 30 2020	n/a	n/a	-US$59m
Mar 31 2020	n/a	n/a	-US$50m
Dec 31 2019	US$5m	US$450k	-US$44m
Sep 30 2019	n/a	n/a	-US$90m
Jun 30 2019	n/a	n/a	-US$86m
Mar 31 2019	n/a	n/a	-US$87m
Dec 31 2018	US$1m	US$133k	-US$82m

Tazminat ve Piyasa: Andrew 'nin toplam tazminatı ($USD 8.83M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 6.60M ).

Tazminat ve Kazançlar: Andrew 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Andrew Cheng (57 yo)

6.2yrs

Görev süresi

US$8,834,907

Tazminat

Dr. Andrew Cheng, MD, PhD, serves as Director of Vera Therapeutics, Inc. since May 2017. He served as Director of Arbutus Biopharma Corporation since August 17, 2019 until May 25, 2022. He served as Chief...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Andrew Cheng	President	6.2yrs	US$8.83m	0.72% $ 17.5m
Jonathan Young	Co-Founder	6.2yrs	US$3.44m	0.36% $ 8.7m
Timothy Rolph	Co-Founder & Chief Scientific Officer	7.6yrs	US$3.49m	0.20% $ 5.0m
William White	Executive VP	5.6yrs	US$4.29m	0.0028% $ 67.9k
Catriona Yale	Executive VP & Chief Development Officer	6.1yrs	US$3.45m	0.051% $ 1.2m
Scott Gangloff	Chief Technical Officer	less than a year	Veri yok	Veri yok
John Schembri	Senior VP & Head of Finance	less than a year	Veri yok	Veri yok
Patrick Lamy	Senior Vice President of Commercial Strategy	1.8yrs	Veri yok	0.0037% $ 89.4k

5.8yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: AKRO 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Andrew Cheng	President	6.8yrs	US$8.83m	0.72% $ 17.5m
Seth Harrison	Independent Director	5.6yrs	US$568.56k	0.41% $ 10.0m
Jane Pritchett Henderson	Independent Director	5.6yrs	US$586.06k	0% $ 0
Mark Iwicki	Independent Chairman of the Board	6yrs	US$606.06k	0% $ 0
Tomas Heyman	Independent Director	4.4yrs	US$581.06k	0% $ 0
Graham L. Walmsley	Independent Director	6.4yrs	US$578.56k	0.0031% $ 76.4k
Yuan Xu	Independent Director	3.6yrs	US$573.56k	0% $ 0
Judy Chou	Independent Director	3.3yrs	US$571.06k	0% $ 0

5.6yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AKRO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.6 yıldır).

Akero Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Recent updates

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Akero Therapeutics: Good Candidate For The MASH Basket

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

New major risk - Revenue and earnings growth

Executive VP notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

New major risk - Revenue and earnings growth

Insufficient new directors

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc

Co-Founder notifies of intention to sell stock

Akero Therapeutics' EFX Data Warrants Caution

Akero Therapeutics, Inc. Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

President notifies of intention to sell stock

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

Price target increased by 13% to US$48.38

Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Akero Therapeutics, Inc. Announces First Patients Dosed in Efruxifermin Phase 3 Synchrony Program

President exercised options and sold US$368k worth of stock

Co-Founder recently sold US$440k worth of stock

Price target decreased by 29% to US$48.44

Akero Therapeutics, Inc. Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

New major risk - Share price stability

Akero Therapeutics, Inc. to Present Results from Phase 2B Symmetry Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

Akero Therapeutics, Inc. Announces Publication of the Harmony Phase 2B Trial Results in the Lancet Gastroenterology & Hepatology

President notifies of intention to sell stock

Price target increased by 7.3% to US$67.75

Price target increased by 7.7% to US$64.75

Insider notifies of intention to sell stock

Akero Therapeutics, Inc. to Report Results of Phase 2b SYMMETRY Study in October 2023

President exercised options and sold US$920k worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from Russell Small Cap Comp Value Index

Co-Founder & Chief Scientific Officer recently sold US$2.1m worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

President exercised options and sold US$1.1m worth of stock

Akero Therapeutics, Inc. Releases Topline Data from an Expansion Cohort of the Phase 2B SYMMETRY Study

President exercised options and sold US$1.1m worth of stock

President notifies of intention to sell stock

President exercised options and sold US$1.2m worth of stock

President exercised options and sold US$1.2m worth of stock

Insider notifies of intention to sell stock

Akero Therapeutics, Inc. Announces the Appointment of Patrick Lamy as Senior Vice President, Commercial Strategy

Co-Founder exercised options and sold US$544k worth of stock

Price target increased to US$52.00

Akero Therapeutics, Inc. Completes Enrollment of Phase 2B SYMMETRY Study

President exercised options and sold US$455k worth of stock

Independent Director recently sold US$1.1m worth of stock

President exercised options and sold US$428k worth of stock

Independent Director recently sold US$12m worth of stock

Price target increased to US$48.33

Co-Founder & Chief Scientific Officer exercised options and sold US$299k worth of stock

Akero Therapeutics announces closing of upsized public offering

President notifies of intention to sell stock

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. Releases Topline Data from HARMONY

Akero adds over 100% rallying peers after NASH success

Akero Therapeutics, Inc. Announces Results from Cohort C of its Phase 2a BALANCED trial in non-alcoholic steatohepatitis

Price target decreased to US$41.67

Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis

Akero Therapeutics, Inc. announced that it expects to receive $100 million in funding from Hercules Capital, Inc.